VC-backed Ovid Therapeutics names business development VP

By Iris Dorbian — 4 months ago

New York-based Ovid Therapeutics Inc, a biopharmaceutical company focused on treating rare and orphan brain diseases, has hired Dr. Anna Kazanchyan as senior vice president of business development. Previously, Dr. Kazanchyan was the founder and managing partner of Primary i-Research LLC. Ovid’s backers included Fidelity Management and Research Company, Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates (on behalf of certain clients), Redmile Group and Cormorant Asset Management.

Continue

Genetic medicine company WAVE Life Sciences nets $66 mln

By Iris Dorbian — 6 months ago

Boston-based genetic medicine company WAVE Life Sciences has closed $66 million in Series B funding. Foresite Capital led the round with participation from other investors that included Fidelity Management and Research Company, New Leaf Venture Partners, Redmile Group, Jennison Associates (on behalf of certain clients), Cormorant Asset Management and RA Capital Management. Leerink Partners served as the placement agent.

Continue

Afferent Pharmaceuticals racks up $55 mln Series C

By Iris Dorbian — 7 months ago

San Mateo, California-based Afferent Pharmaceuticals, a developer of drugs that treat neurogenic respiratory, urologic and pain disorders, has closed $55 million in Series C funding. Fidelity Management & Research Company led the round with participation from other investors that included Jennison Associates LLC (on behalf of certain clients), New Leaf Ventures, Partner Fund Management, Redmile Group, Tekla Healthcare Investors and Tekla Life Science Investors.

Continue

Dimension Therapeutics nets $65 mln Series B

By Iris Dorbian — 10 months ago

Cambridge, Massachusetts-based Dimension Therapeutics Inc, which is focused on developing treatments for liver disorders, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, Tourbillon Global Ventures, Fidelity Biosciences and OrbiMed. In addition to the funding, Dr. Mike Dybbs, a partner at New Leaf Venture Partners, has been added to Dimension’s board of directors.

Continue

Natera reels in about $55.5 mln

By Iris Dorbian — 10 months ago

San Carlos, California-based Natera Inc, a provider of non-invasive genetic testing, has secured about $55.5 million in funding. Sofinnova Ventures led the round with participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors. In conjunction with the funding, Dr James Healy, a general partner at Sofinnova, has been appointed to Natera’s board of directors.

Continue

Aeglea Biotherapeutics snags $44 mln Series B

By Iris Dorbian — 11 months ago

Aeglea Biotherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has raised $44 million in Series B funding. Return backers Lilly Ventures and Novartis Venture Fund led the round with participation from other investors that included UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.

Continue

Aduro Biotech nets $51.4 mln Series D

By Iris Dorbian — 1 year ago

Berkeley, Calif.-based immuno-oncology firm Aduro Biotech has received $51.4 million in Series D financing. The investors included OrbiMed, Janus Capital Management, Franklin Advisers and Foresite Capital Management. Leerink Partners served as placement agent.

Continue

Flex Pharma raises $40 mln from big investor group

By Chris Witkowsky — 1 year ago

Flex Pharma, a biopharmaceutical company focused on treatments for neuromuscular disorders, has raised $40 million from an investor group. Investors include Longwood Fund, Bessemer Venture Partners, EcoR1 Capital, Jennison Associates, Lightstone Ventures, Alexandria Equities, CD-Venture, Bindley Capital Partners, City Hill Ventures and several individuals including Steve Pagliuca, managing director at Bain Capital.

Continue

Bellicum Pharmaceuticals nabs $55 mln Series C

By Iris Dorbian — 1 year ago

Bellicum Pharmaceuticals has closed $55 million in Series C funding. The investors included funds managed by RA Capital Management, Perceptive Advisors, Jennison Associates (on behalf of certain clients), Sabby Capital and Ridgeback Capital Management. Jefferies was the placement agent. Based in Houston, Bellicum Pharmaceuticals is a biotech firm focused on developing cellular immunotherapies.

Continue